TPM
HAE icon

Triasima Portfolio Management’s Haemonetics HAE Stock Holding History

Triasima Portfolio Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,665
Closed -$507K – 140
2023
Q3 		$507K Hold
5,665
– – 0.05% 104
2023
Q2 		$639K Buy
5,665
+1,435
+34% +$121K 0.04% 107
2023
Q1 		$350K Buy
+4,230
New +$342K 0.03% 113

Other funds holding HAE

Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Triasima Portfolio Management's HAE Position: Q4 2023 in Review

Triasima Portfolio Management sold out of Haemonetics (HAE) in Q4 2023, closing a stake of 5,665 shares — an estimated $507K sold.

Triasima Portfolio Management first reported a position in HAE in Q1 2023 and held it in 3 quarters. The position peaked at $639K in Q2 2023. 295 funds tracked by Wall St. Rank hold HAE as of Q4 2023.

  • Triasima Portfolio Management reported no remaining Haemonetics position as of Q4 2023 after selling out during the quarter.
  • Triasima Portfolio Management sold 5,665 Haemonetics shares in Q4 2023, an estimated $507K.
  • Triasima Portfolio Management first reported a position in Haemonetics in Q1 2023 and held it in 3 quarters.
  • Triasima Portfolio Management's Haemonetics position peaked at $639K in Q2 2023.
  • 295 funds tracked by Wall St. Rank held Haemonetics as of Q4 2023.

Based on Triasima Portfolio Management's 13F filing for Q4 2023, filed 29 Jan 2024.